Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077758 | 0.89 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL674693 | 0.86 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL3641955 | 0.85 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL14261140 | 0.84 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL6076130 | 0.84 | HDAC1 (0.64) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL6078618 | 0.84 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL1689286 | 0.84 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL6243828 | 0.84 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL675168 | 0.84 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC6HDAC4 | |
| SCHEMBL29603842 | 0.84 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101279927-A | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | claimed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| CN-1723192-A | Arylene-carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-01-18 | — | — | CN | claimed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | claimed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | claimed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | claimed |
| CN-101279927-A | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| CN-1723192-A | Arylene-carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-01-18 | — | — | CN | disclosed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | MKI67, API5, ACIN1 | HDAC1 757/4885HDAC2 619/4885HDAC3 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.